Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 3
2009 pubmed 14 citations

Antimicrobial peptide inhibition of Porphyromonas gingivalis 381-induced hemagglutination is improved with a synthetic decapeptide.

Dixon. Douglas R DR; Jeffrey. Nicole R NR; Dubey. Vinod S VS; Leung. Kai P KP

Key Findings

  • LL‑37 was the most potent peptide at stopping P. gingivalis‑induced hemagglutination
  • The synthetic decapeptide KSL‑W alone was weak but enhanced the inhibition when combined with LL‑37 or histatin 5
  • KSL‑W did not cause erythrocyte agglutination at any tested concentration, unlike LL‑37

Practical Outcomes

  • A mouth‑wash or oral spray that mixes LL‑37 (or histatin 5) with the synthetic peptide KSL‑W could give better protection against the gum‑pathogen P. gingivalis. However, the effective doses are high and have only been tested in lab dishes, so more safety and dosing work is needed before real‑world use.

Summary

The study shows that the natural antimicrobial peptide LL‑37 can block a key step (hemagglutination) that Porphyromonas gingivalis uses to stick to cells, and that a small lab‑made peptide called KSL‑W makes this blocking effect even stronger when used together. LL‑37 works best, histatin 5 is also good, and KSL‑W alone isn’t very strong but doesn’t cause unwanted blood‑cell clumping.

Abstract

The effects of various antimicrobial peptides (AMPs) on disrupting the hemagglutinating ability of cellular components of the putative oral pathogen Porphyromonas gingivalis were examined. AMP inhibition of P. gingivalis 381-induced hemagglutination using vesicles (VES) or outer membrane (OM) preparations was determined within standardized hemagglutination assays using various mammalian erythrocytes. A synthetic decapeptide (KSL-W) and its truncated peptide analogs were evaluated and compared with selected classes of AMPs derived from naturally occurring innate defense peptides. All tested AMPs were effective in disrupting P. gingivalis-induced hemagglutination among tested erythrocytes, with the exception of magainin I and the truncated KSL-W analogs. LL-37 was generally the most potent followed by histatin 5. The synthetic decapeptide (KSL-W) was found to be similar to the histatin 8 peptide in terms of inhibitory effect. In addition, co-application assays (with selected oral-related AMPs+/-KSL-W) were employed to determine if co-application procedures would improve hemagglutination abrogation above that of oral-related AMPs alone. These experiments revealed that the KSL-W peptide improved hemagglutination inhibition above that of each of the oral-related peptides (histatin 5 and 8, LL-37) alone. Among mammalian erythrocytes, significant peptide-induced hemagglutination was observed for the cathelicidin class AMPs, LL-37 and indolicidin (>or=25 and >or=100 microM respectively). In contrast, KSL-W did not induce erythrocyte agglutination throughout any concentration range tested (0.1-1000 microM). Our results suggest that several AMPs are effective in disrupting P. gingivalis 381-induced hemagglutination and that the co-application of a small, synthetically derived peptide may serve to augment the role of local host AMPs engaged in innate defense.

Study Information

Provider

pubmed

Year

2009

Date

2009-08-08T00:00:00.000Z

DOI

10.1016/j.peptides.2009.07.027

Citations

14

References

43